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Objectives: To investigate the association of the Charlson Comorbidity 
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Index (CCI) with clinical outcomes after TAVI.  
Background: Patients undergoing transcatheter aortic valve implantation 
(TAVI) have high comorbid burden, but evidence around the impact of 
comorbidity on clinical outcomes is limited.  
Methods: Data from 1887 patients from the UK, Canada, Spain, 
Switzerland and Italy were collected between 2007 and 2016. The 
association of CCI with 30-day mortality, Valve Academic Research 
Consortium-2 (VARC-2) composite early safety, long-term survival and 
length of stay (LOS) was calculated using logistic regression and Cox 
proportional hazard models, as a whole cohort and at a country-level, 
through a two-stage individual participant data (IPD) random-effect meta-
analysis.  
Results: Most patients had a CCI≥3 (60%). A weak correlation was found 
between the total CCI and four different preoperative risks scores (ρ=0.16 
to 0.29), and approximately 50% of patients classed as low risk from four 
risk prediction models still presented with a CCI≥3. Per-unit increases in 
total CCI were not associated with increased odds of 30-day mortality (OR 
1.09, 95% CI: 0.96-1.24) or VARC-2 early safety (OR 1.04, 95%CI: 0.96-
1.14), but was associated with increased hazard of long-term mortality (HR 
1.10, 95%CI: 1.05-1.16). The two-stage IPD meta-analysis indicated that 
CCI was not associated with LOS (HR 0.97, 95%CI: 0.93-1.02).  
Conclusion: In this multi-centre international study, patients undergoing 
TAVI had significant comorbid burden. We found a weak correlation 
between the CCI and well-established preoperative risks scores. The CCI 
had a moderate association with long-term mortality up-to 5-years post 
TAVI.  
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Abstract 
Objectives: To investigate the association of the Charlson Comorbidity Index (CCI) with clinical 
outcomes after TAVI. 
Background: Patients undergoing transcatheter aortic valve implantation (TAVI) have high 
comorbid burden, but evidence around the impact of comorbidity on clinical outcomes is limited.  
Methods: Data from 1887 patients from the UK, Canada, Spain, Switzerland and Italy were 
collected between 2007 and 2016. The association of CCI with 30-day mortality, Valve 
Academic Research Consortium-2 (VARC-2) composite early safety, long-term survival and 
length of stay (LOS) was calculated using logistic regression and Cox proportional hazard 
models, as a whole cohort and at a country-level, through a two-stage individual participant data 
(IPD) random-effect meta-analysis. 
Results: Most patients had a CCI≥3 (60%). A weak correlation was found between the total CCI 
and four different preoperative risks scores (ρ=0.16 to 0.29), and approximately 50% of patients 
classed as low risk from four risk prediction models still presented with a CCI≥3. Per-unit 
increases in total CCI were not associated with increased odds of 30-day mortality (OR 1.09, 
95% CI: 0.96-1.24) or VARC-2 early safety (OR 1.04, 95%CI: 0.96-1.14), but was associated 
with increased hazard of long-term mortality (HR 1.10, 95%CI: 1.05-1.16). The two-stage IPD 
meta-analysis indicated that CCI was not associated with LOS (HR 0.97, 95%CI: 0.93-1.02). 
Conclusion: In this multi-centre international study, patients undergoing TAVI had significant 
comorbid burden. We found a weak correlation between the CCI and well-established 
preoperative risks scores. The CCI had a moderate association with long-term mortality up-to 5-
years post TAVI.  
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Key message: 
• The majority of patients who underwent TAVI presented with severe comorbid burden as 
defined by a CCI of ≥3.  
• We found a weak correlation between the CCI and well-established preoperative risks scores, 
and even patients classed as low preoperative risk presented with a CCI≥3 in approximately 
50% of the cases.  
• The CCI was moderately associated with increased hazard of mortality up-to 5-years post 
TAVI. 
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INTRODUCTION 
In patients with severe symptomatic aortic stenosis (AS) who are considered at high or 
intermediate operative risk, transcatheter aortic valve implantation (TAVI) has become a standard 
alternative to surgical aortic valve replacement (SAVR)(1-3). 
Validated scoring systems permit the estimation of operative risk according to patients’ 
clinical profile and the type of intervention(4-8). However, these scoring systems are elaborated 
from large “general” populations and might lack predictive accuracy in specific subgroups, 
particularly elderly patients with valvular heart disease and multiple comorbid conditions. 
The Charlson Comorbidity Index (CCI) is a global measure of comorbidity burden that was 
developed and validated for estimating prognosis and adverse clinical outcomes in a broad 
spectrum of patients with multiple coexisting illnesses(9-11). While the Heart Team considers the 
presence of multiple comorbid conditions of patients during their decision-making processes for 
TAVI eligibility, the association of comorbid bu den with clinical outcomes is mainly limited to 
single centre studies(12,13) with relatively small sample sizes. Therefore, the aim of this multi-
centre international study was to report the distribution of comorbidity burden in patients 
undergoing TAVI and the association with short and long-term clinical outcomes, as well as 
length of stay (LoS) after TAVI. 
METHODS 
Participants 
 This analysis included prospective data collected between 2007 and 2016 on all TAVI 
procedures undertaken across four UK-TAVI centres (Queen Elizabeth Hospital (Birmingham), 
University Hospital of North Staffordshire (Stoke-On-Trent), University Hospital of Wales 
(Cardiff) and New Cross Hospital (Wolverhampton)), and four non-UK TAVI centres 
(University Hospital, London Health Sciences Centre (Ontario, Canada), Cardiovascular 
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Institute, Hospital Clínico San Carlos (Madrid, Spain), Heart Center Lucerne (Lucerne, 
Switzerland) and University Hospital of Udine (Udine, Italy). The UK derived data were 
extracted from those submitted to the UK TAVI registry(14,15), while the non-UK data were 
derived from each individual centre’s databases. The variables recorded across all 
centres/countries included patient baseline demographics, pre-procedural risk factors, peri/post-
procedural information and outcomes occurring before index hospital discharge. For UK patients, 
all-cause long-term mortality information was available through linkage with the Office for 
National Statistics, and for non-UK patients, this information was collected either by last 
available on-site clinical visit or by telephone contacts. The research ethics boards at the 
participating sites approved the datasets for the study. 
Comorbidity burden measurement 
 The CCI was utilized as a measure of comorbid burden(16), and was retrospectively 
calculated for each patient across all contributing centres. The 19 components of CCI are: 
previous myocardial infarction, congestive heart failure, peripheral vascular disease, 
cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue 
disease, peptic ulcer disease, mild or severe liver disease, diabetes with or without end-organ 
damage, moderate-severe chronic kidney disease, hemiplegia, leukemia, lymphoma, any tumour 
with or without metastases and Acquired Immune Deficiency Syndrome status. Each of the 
components has an associated weighting, which is summed across the 19 co ditions to define the 
total CCI score; thus, total CCI can range from 0 to 37 points, with higher values indicating 
increasing comorbid burden.  
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Statistical Analysis 
Continuous data were described using the mean and range of values, with group 
comparisons made using analysis of variance (ANOVA). Likewise, categorical data were 
presented as raw number of events and corresponding percentages, with comparisons made using 
the chi-squared test. The primary outcomes in this analysis were 30-day mortality and long-term 
survival. Secondary outcomes were LoS (defined as the number of days between admission and 
discharge) and the Valve Academic Research Consortium-2 (VARC-2) composite early safety 
endpoint (defined as any of the following occurring within 30-days: mortality, stroke, life-
threatening bleed, acute kidney injury, coronary artery obstruction, major vascular complication, 
and valve-related dysfunction)(17). The impact of comorbidity on each outcome was examined 
with total CCI modelled as both a continuous variable (i.e. the effect of per-unit increases in total 
CCI), and across strata of CCI=0, CCI=1, CCI=2 and CCI≥3 (to examine non-linear relationships 
between total CCI and the outcomes).  
Patients with missing information that precluded CCI calculation were excluded from the 
analysis. Similarly, patients with missing endpoint data were removed from the analysis of that 
specific endpoint. Missing covariate information was imputed using multiple imputation by 
chained equations, where we generated ten imputed datasets(18). The imputation models for each 
covariate included the majority of other baseline covariates, total CCI, each of the considered 
endpoints, and a random-effect at the country-level(19,20). All subsequent analyses were 
performed within each imputed dataset, with parameters of interest pooled across imputations 
using Rubin’s rules(18). 
Baseline patient risk was summarised with the Logistic EuroSCORE (LES)(5), the 
EuroSCORE-II (ESII)(21), Society of Thoracic Surgeons (STS) Predicted Risk of Mortality(8), 
and the TAVI-specific FRANCE-2(22) prediction models. These models were calculated in the 
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multiple imputed data and were therefore averaged across imputations. Spearman’s rank 
correlation coefficients were calculated to determine the strength of the correlation between total 
CCI and each risk model.  
Associations between CCI and the binary endpoints (30-day mortality/VARC-2 composite 
early safety) were examined with logistic regression, with unadjusted, age and sex adjusted, and 
multivariable adjusted odds ratios (ORs) reported. Similarly, the effect of CCI on long-term 
survival and LOS was examined non-parametrically using Kaplan-Meier plots, with 
multivariable adjusted hazard ratios (HRs) estimated with Cox proportional hazards models. 
Long-term survival was modelled up-to 5 years post-procedural follow-up. 
Each of the multivariable adjustments included all baseline/procedural variables that were 
(a) recorded across all the datasets, and (b) not components of the CCI, or on the causal pathway 
between CCI and outcome. Specifically, the following variables were included in the 
multivariable adjustment: age, sex, smoking status, atrial fibrillation, height, weight, Canadian 
Cardiovascular Society (CCS) class IV, New York Heart Association (NYHA) Functional 
Classification, coronary artery disease, pulmonary hypertension (>60 mmHg), aortic valve area, 
left ventricular ejection fraction (LVEF), non-elective procedure indication, and non-transfemoral 
access route indication. 
 When analysing the data as a whole cohort, we included a random effect (i.e. random 
intercept) at a country-level within each of the analysis models, thereby aiming to respect the 
clustering of the data collection. Similarly, we also performed a two-stage individual participant 
data (IPD) meta-analysis at a country-level. Here, data from each country were analysed 
individually, and the results from which were then pooled using a random effects model across 
countries(23,24). The multiple imputation was incorporated into this process by first applying 
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Rubin’s rules at the country-level prior to pooling the country-specific estimates using meta-
analytical techniques(25).  
All analyses were performed using R version 3.4.2(26). Graphical plots were made using 
the “ggplot2” package(27), the “mice” package was used for the multiple imputation(28), and the 
meta-analysis was performed with the “metafor” package(29). 
RESULTS 
Between August 2007 and September 2016, data for n=1887 patients were available, 
comprising 791, 308, 181, 375, 232 patients from the UK, Canada, Italy, Spain and Switzerland, 
respectively. Patient baseline characteristics as a whole cohort and across strata of CCI are given 
in Table 1; similarly, Supplement ry Table 1 presents baseline characteristics by country. The 
mean age of patients was 81.6 years with 51.4% male. Most procedures were undertaken 
electively and via transfemoral access (83%). The proportion of patients with atrial 
fibrillation/flutter (P=0.041), previous cardiac surgery (P=0.020), previous balloon-aortic 
valvuloplasty (P=0.003), previous percutaneous coronary intervention (P<0.001), NYHA class 
III/IV (P=0.002), coronary artery disease (P<0.001), LVEF<50% (P<0.001) and undergoing non-
elective procedures (P=0.046) varied significantly across strata of total CCI (Table 1). 
The distribution of total CCI for the whole cohort and by country is given in Figure 1. The 
median total CCI was 3 (interquartile range: 2-4), with a minimum of 0 and maximum of 11. 
Across all countries, the majority of patients had a total CCI of 3 or more, with the proportion of 
patients with CCI≥3 ranging from 56% (UK) to 72% (Switzerland) (Supplementary Figure 1). 
The most common cardiovascular comorbidities were previous myocardial infarction (24%) and 
congestive heart failure (59%), while the most common non-cardiovascular comorbidities were 
chronic kidney disease (50%) and chronic obstructive pulmonary disease (21%) (Supplementary 
Figure 2). 
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CCI and Established Risk Models 
We calculated the LES, ESII, STS and the TAVI-specific FRANCE-2 prediction models 
for all patients. Unsurprisingly, the proportion of patients with CCI≥3 increased across quantiles 
of the predicted risks from each model (Figure 2). Nevertheless, within the lowest predicted risk 
quantile, the proportion of patients with a CCI≥3 was 50.2%, 48.5%, 46.8% and 50.4% for LES, 
ESII, STS and FRANCE-2, respectively, with a weak Spearman’s rank correlation coefficient 
between the total CCI and predicted LES (ρ=0.21, 95%CI: 0.16-0.25), ESII (ρ=0.21, 95%CI: 
0.16-0.25), STS (ρ=0.28, 95%CI: 0.24-0.32), and FRANCE-2 (ρ=0.16, 95%CI: 0.12-0.20) score.  
30-day and long-term mortality 
 Data on 30-day mortality were available in 1644 (87%) patients, of which, 68 (4.14%) died 
within 30 days post TAVI. There was no significant difference in crude 30-day mortality rates 
with either per-unit increase in total CCI (OR: 1.11, 95% CI: 0.98-1.25; Table 2), or across CCI 
strata (P=0.312) with 30-day mortality rates of 1.06%, 4.33%, 3.29%, and 4.67% for CCI=0, 
CCI=1, CCI=2 and CCI≥3, respectively. Similarly, the multivariable adjusted odds for 30-day 
mortality were not significantly different for unit increases in total CCI (OR: 1.09, 95% CI: 0.96-
1.24; Table 2). Across the UK, Canadian, Italian, Spanish and Swiss TAVI centres, the crude 
proportions of 30-day mortality were 20/567 (3.53%), 15/308 (4.87%), 5/162 (3.09%), 25/375 
(6.67%), and 3/232 (1.29%), respectively (P=0.016). The two-stage IPD meta-analysis showed 
that the multivariable adjusted odds of 30-day mortality were significa tly higher per unit 
increase in total CCI for UK patients (OR 1.36, 95%CI: 1.08-1.71), but no significant differences 
in 30-day mortality rates were found in patients from other countries, with a pooled OR of 1.12 
(95%CI: 0.88-1.41) (Supplementary Figure 3).  
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A total of 1555 patients had data on long-term survival, totalling 3663 person-years of 
follow-up. The overall six-month, one-year and two-year survival estimates were 91.0%, 87.9% 
and 79.8%, respectively. Across CCI strata, one-year survival rates were 95.1%, 89.3%, 90.6% 
and 85.9% for CCI=0, CCI=1, CCI=2 and CCI≥3, respectively (Figure 3, log-rank P<0.001). A 
univariable Cox proportional hazards model indicated that the hazard of mortality was 
significantly higher for unit increases in total CCI (HR 1.11, 95%CI 1.06-1.16; Table 2). The 
hazards of mortality remained significantly higher for unit increases in total CCI after adjusting 
for age and sex (HR 1.11, 95%CI: 1.06-1.17), and after multivariable adjustment (HR 1.10, 
95%CI: 1.05-1.16). Similarly, long-term survival differed significantly across strata of total CCI 
with a multivariable adjusted HR of 1.73 (95%CI: 1.01-2.94) for patients with CCI=2 and 2.18 
(95%CI: 1.36-3.61) for those with CCI≥3 as compared with those with a CCI=0 (Table 3). The 
two-stage IPD meta-analysis on hazards for long-term mortality across each participating country 
resulted in a pooled HR (multivariable adjusted) of 1.13 (95%CI: 0.98-1.30) per unit increases in 
total CCI (Figure 4).  
Length of Stay 
 Across the whole cohort, 1820 (96%) patients had information on their LoS, with a median 
LoS of 7 days (interquartile range 5-13 days). Unit increases in total CCI were not associated 
with longer LoS after multivariable adjustment (HR: 1.00, 95%CI: 0.97-1.02; Table 2). Similar 
findings were observed within the two-stage IPD meta-analysis with a combined meta-analysis 
HR of 0.97 (95%CI: 0.93-1.02; Figure 4). 
Analyses for non-linear relationships between CCI and LoS indicated that the multivariable 
adjusted HRs for a shorter LoS were 1.31 (95%CI: 1.02, 1.68), 1.41 (95%CI: 1.11-1.79) and 1.27 
(95%CI: 1.02-1.59) for patients with CCI=1, CCI=2 and CCI≥3, respectively, as compared to 
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those with CCI=0 (Table 3). Comparable results were observed when we modelled the 
(multivariable adjusted) HR for a shorter LoS as a smooth function of total CCI (Figure 5).  
The two-stage IPD meta-analysis for LoS, indicated that UK patients with at least 1 co-
morbid condition (i.e. CCI>0) had a significantly shorter LoS compared with UK patients with a 
CCI=0 (Supplementary Figure 4). However, the pooled IPD meta-analysis results showed no 
significant difference in LoS across strata of total CCI, with pooled HRs of 0.89 (95%CI: 0.44-
1.80), 1.07 (95%CI: 0.66-1.73) and 0.92 (95%CI: 0.54-1.54), for CCI=1, CCI=2, CCI≥3, 
respectively, compared with CCI=0 (Supplementary Figure 4).  
VARC-2 Composite Early Safety 
A total of 745 patients were removed due to missing data on the VARC-2 composite early 
safety outcome (i.e. patients who were missing components of the composite outcome). Hence, 
1142 (60.5%) patients had information on the VARC-2 composite early safety outcome, of 
which, the event rate was 18.6%. Across strata of CCI, the event rate was 13/69 (18.8%), 37/201 
(18.4%), 26/207 (12.6%) and 136/665 (20.5%) for CCI=0-CCI=1-CCI=2 and CCI≥3, 
respectively (P=0.089). After multivariable adjustment, the odds of the VARC-2 composite early 
safety outcome were not significantly different with per-unit increases in total CCI (Table 2) or 
across strata of total CCI (Table 3). 
DISCUSSION 
In this multi-centre international study, the majority of patients who underwent TAVI 
presented with severe comorbid burden as defined by a CCI of ≥3. We found a weak correlation 
between the CCI and well-established preoperative risks scores, and even patients classed as low 
preoperative risk presented with a CCI≥3 in approximately 50% of the cases. While UK patients 
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with a CCI between 1 and 3 had shorter LoS, this finding was not observed within the other non-
UK centres. The CCI was associated with increased hazard of mortality up-to 5-years post TAVI.  
The CCI is a validated tool to assess comorbidity burden and has been shown to be a 
predictor of outcome in patients with aortic stenosis(12,13,30,31). However, we may have to 
consider selection bias since TAVI candidates with a CCI=0 are unlikely to be truly “without 
comorbidity” and may merely have prevalent comorbid conditions not captured by the CCI. 
Explicitly, it is likely that patients undergoing TAVI presenting a CCI=0 are more comorbid as 
compared to those in the general population by virtue of the fact that they are considered not 
suitable for SAVR. Some of the few exemptions to this might be old patients (i.e. >85 years), 
who, solely because of their age, will benefit from a TAVI procedure rather than SAVR(3,32), 
regardless if they are considered low surgical risk. Therefore, the cohort of patients with a CCI=0 
are likely to represent a high-risk cohort by virtue of other comorbid conditions not captured by 
CCI or frailty. 
Pre-operative risk assessment 
The utility of the STS score and the logistic EuroSCORE on patients being evaluated for 
TAVI is limited(33). Indeed, the poor performance of these scores are due to the fact that they 
were derived for predicting surgical outcomes and are not calibrated to perform in TAVI 
procedures in which patients are excluded from SAVR by virtue of certain comorbidities, such as 
porcelain aorta, chest radiation/hostile chest, cancer, immunodeficiency, liver disease/cirrhosis, 
and frailty, that, among others, are not computed into the risk models. A such, this may translate 
into an incorrect decision-making processes, but also, it might artificially exaggerate the positive 
results obtained with either surgical or transcatheter procedures(34). Our results show a weak 
correlation between the CCI and STS score, LES, ESII and FRANCE-2 scores. Importantly, even 
those patients classed as low preoperative risk were still relatively comorbid as defined by a 
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CCI≥3 in approximately 50% of the patients. These results suggest that the risk models do not 
capture several aspects of preoperative risk. 
Comorbidity burden and mortality 
Our results indicate that comorbidity burden assessed by the CCI was not associated with 
significantly higher odds of 30-day mortality, yet, it was in the long-term. These results are in 
line with previous reports(12,13,35). A potential explanation is that procedural-related variables 
have a greater impact on in-hospital and 30-day mortality (35,36), but (other than stroke within 
30 days) procedural variables do not impact long-term survival following TAVI (36). These 
findings support the theory that comorbid conditions have a greater impact on long-term 
mortality than the index TAVI procedure. Indeed, it is known that moderate to high-risk patients, 
the majority die from non-cardiac conditions(13,35,37,38). The current analysis suggests that 
CCI score moderately correlated with survival up-to 5-year post procedure across multiple 
countries/centres, each with different practices and valve types. Hence, further supporting the 
notion that if the patient gets through the procedure, then again, mortality is driven by the 
common comorbid states that general ageing features ensure take over. Therefore, the use of CCI 
may potentially serve as a measure to estimate long-term mortality as compared to standard risk 
assessment. 
Comorbidity Burden and Length of Stay 
 The results from this analysis indicate that CCI was generally not associated with LoS. UK 
patients with a higher total CCI were significantly more likely to be discharged earlier than those 
with a CCI=0, but this was not observed across all countries. One needs to interpret these 
findings with caution given that LoS is driven by several clinical but also non-clinical factors 
such as home circumstances and country or centre-specific practices for discharge. Moreover, 
certain centers with a predominant use of self-expanding TAVI devices, may delay discharge due 
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to perceived need for latter permanent pacemaker implantation. Additionally, the time period for 
the analysis (2007-2016) covers temporal changes to TAVI practice such as the introduction of 
conscious sedation and new devices technology, thus, potentially weakening comorbidity and 
LoS associations; future analyses on contemporary cohorts of TAVI patients could investigate 
this further. 
Limitations 
Several limitations need to be considered. Firstly, although our results were obtained from 
prospectively gathered datasets, the retrospective nature of the analysis are exposed to potential 
(unmeasured) confounders. Therefore, we cannot interpret the results as causal, but rather they 
represent associations between CCI and the investigated outcomes. Secondly, in most centers we 
only had data on CCI as a quantification of comorbid burden. Although this is a widely used and 
validated measure of estimating prognosis and adverse clinical outcomes, the findings may differ 
if other comorbidity scales were used. Finally, as discussed above, selection bias needs to be 
considered in this context, since TAVI patients with a CCI=0 are unlikely to be representative of 
those in the general population with CCI=0. 
Conclusion 
In this multi-centre, international study, the majority of patients who underwent TAVI 
presented with 3 or more comorbid conditions as assessed by the CCI. We found a weak 
correlation between the CCI and well-established preoperative risks scores and, even those 
patients classed as low preoperative risk presented with a CCI≥3 in about 50% of the patients. 
While the 30-day mortality rates were significantly higher per unit increase in total CCI for UK 
patients, no statistically significant differences were found in patients from other countries. The 
CCI was associated with increased hazard of mortality up-to 5-years post TAVI, suggesting that 
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CCI is a potentially useful measure to assess long-term outcomes compared with standard risks 
assessment. 
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Tables 
Table 1: Baseline Patient Characteristics and Post-Procedural Outcomes as a Whole Cohort and Across Each Strata of Charlson 
Comorbidity Index (CCI). 
 
Variable Overall (n=1887) CCI=0 (n=104) CCI=1 (n=276) CCI=2 (n=373) CCI≥3 (n=1134) P-value 
Age, mean (min-max) [missing] 81.6 (23-96) [0] 82.8 (43-94) 81.4 (23-94) 81.8 (51-96) 81.4 (44-95) 0.256 
Male, n (%) [missing] 970 (51.4) [0] 49 (47.1) 131 (47.5) 165 (44.2) 625 (55.1) <0.001 
Diabetic, n (%) [missing] 564 (29.9) [2] 8 (7.69) 32 (11.6) 91 (24.4) 433 (38.2) <0.001 
Current or Ex-smoker, n (%) 
[missing] 
750 (39.7) [239] 34 (32.7) 115 (41.7) 131 (35.1) 470 (41.4) 0.063 
Creatinine, mean (min-max) 
[missing] 
108.6 (0-638) [3] 89.6 (42-281) 83.6 (38-250) 94.3 (36-638) 121.2 (0-579) <0.001 
Dialysis, n (%) [missing] 18 (0.95) [413] 2 (1.92) 0 (0) 4 (1.07) 12 (1.06) 0.275 
Previous MI, n (%) [missing] 429 (22.7) [0] 8 (7.69) 42 (15.2) 66 (17.7) 313 (27.6) <0.001 
Pulmonary Disease, n (%) 
[missing] 
469 (24.9) [5] 7 (6.73) 51 (18.5) 82 (22.0) 329 (29.0) <0.001 
Neurological Disease, n (%) 
[missing] 
320 (17.0) [2] 6 (5.77) 39 (14.1) 44 (11.8) 231 (20.4) <0.001 
Extracardiac Arteriopathy, n (%) 
[missing] 
401 (21.3) [2] 12 (11.5) 46 (16.7) 57 (15.3) 286 (25.2) <0.001 
Atrial Fibrillation/Flutter, n (%) 549 (29.1) [10] 20 (19.2) 80 (29.0) 98 (26.3) 351 (31.0) 0.041 
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[missing] 
Previous cardiac surgery, n (%) 
[missing] 
479 (25.4) [0] 32 (30.8) 88 (31.9) 86 (23.1) 273 (24.1) 0.020 
Previous BAV, n (%) [missing] 322 (17.1) [578] 14 (13.5) 27 (9.78) 69 (18.5) 212 (18.7) 0.003 
Previous PCI, n (%) [missing] 367 (19.4) [313] 14 (13.5) 37 (13.4) 56 (15.0) 260 (22.9) <0.001 
Height-mean (min-max) 
[missing] 
1.64 (1.32-1.90) [213] 1.65 (1.38-1.90) 1.64 (1.44-1.89) 1.63 (1.40-1.90) 1.64 (1.32-1.90) 0.033 
Weight, mean (min-max) 
[missing] 
73.7 (40-135.9) [212] 71.7 (46-95) 72.6 (44-136) 72.1 (40-131) 74.7 (41-132) 0.009 
CCS IV, n (%) [missing] 20 (1.06) [1017] 0 (0) 3 (1.09) 5 (1.34) 12 (1.06) 0.706 
NYHA III/IV, n (%) [missing] 1546 (81.9) [12] 76 (73.1) 226 (81.9) 289 (77.5) 955 (84.2) 0.002 
Coronary Artery Disease, n (%) 
[missing] 
960 (50.9) [4] 40 (38.5) 130 (47.1) 170 (45.6) 620 (54.7) <0.001 
Pulmonary Hypertension, n (%) 
[missing] 
265 (14.0) [645] 8 (7.69) 35 (12.7) 50 (13.4) 172 (15.2) 0.157 
Aortic Valve area, mean (min-
max) [missing] 
0.68 (0.20-4.0) [429] 0.68 (0.20-2.00) 0.67 (0.26-3.71) 0.67 (0.20-2.80) 0.69 (0.20-4.00) 0.573 
LVEF <50%, n (%) [missing] 691 (36.6) [27] 25 (24.0) 93 (33.7) 112 (30.0) 461 (40.7) <0.001 
Non-elective procedure, n (%) 
[missing] 
217 (11.5) [608] 5 (4.81) 32 (11.6) 31 (8.31) 149 (13.1) 0.010 
Non-TF Access, n (%) 329 (17.4) 19 (18.3) 41 (14.9) 54 (14.5) 215 (19.0) 0.143 
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Logistic EuroSCORE, mean % 
(min-max)* 
24.8 (1.72-98.0) 18.1 (4.83-75.6) 22.4 (1.72-75.9) 21.4 (2.97-73.6) 27.1 (2.15-98.0) <0.001 
STS-Score, mean % (min-max)* 5.33 (0.59-48.6) 3.70 (1.16-19.7) 4.02 (0.70-13.7) 4.53 (0.88-14.7) 6.05 (0.59-48.6) <0.001 
EuroSCORE II, mean % (min-
max)* 
8.21 (0.78-66.0) 5.94 (1.75-25.4) 6.89 (0.91-35.9) 6.63 (1.03-34.0) 9.26 (0.78-66.0) <0.001 
FRANCE-2, mean % (min-
max)* 
9.24 (3.49-40.6) 7.43 (3.49-28.9) 8.20 (3.49-27.1) 8.87 (3.49-28.9) 9.78 (3.49-40.6) <0.001 
Outcomes       
30-day mortality, n (%) 68/1644 (4.14%) 1/94 (1.06%) 10/231 (4.33%) 11/334 (3.29%) 46/985 (4.67%) 0.312 
1-Year survival, % 87.9% 95.1% 89.3% 90.6% 85.9% <0.001 
Length of Stay, median (days) 7 8 7 7 8 0.018 
VARC-2 Early safety, n (%) 212/1142 (18.6%) 13/69 (18.8%) 37/201 (18.4%) 26/207 (12.6%) 136/665 (20.5%) 0.089 
 
*The Logistic EuroSCORE, STS-Score and EuroSCORE II each aim to predict short-term mortality following cardiac surgery; the FRANCE-2 model is a 
TAVI specific model to estimate 30-day mortality risk. All risk models were calculated here using the multiple imputed data. MI: myocardial infarction. 
BAV: balloon-aortic valvuloplasty. PCI: percutaneous coronary intervention. CCS: Canadian Cardiovascular Society. NYHA: New York Heart Association. 
LVEF: left ventricular ejection fraction. TF: transfemoral. VARC: Valve Academic Research Consortium. 
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Table 2: Differences in 30-day Mortality, Long-term Survival and Length of Stay Per 
Unit Increases in Total Charlson Comorbidity Index for the whole cohort. 
 
30-day mortality OR (95% CI) 
Univariable 1.11 (0.98-1.25) 
Age and Sex adjusted 1.13 (1.00-1.27) 
Multivariable* 1.09 (0.96-1.24) 
  
VARC-2 Early Safety OR (95% CI) 
Univariable 1.08 (1.00-1.16) 
Age and Sex adjusted 1.08 (1.00-1.17) 
Multivariable* 1.04 (0.96-1.14) 
  
Long-term Survival HR (95% CI) 
Univariable 1.11 (1.06-1.16) 
Age and Sex adjusted 1.11 (1.06-1.17) 
Multivariable* 1.10 (1.05-1.16) 
  
Length of Stay HR (95% CI) 
Univariable 0.96 (0.94-0.98) 
Age and Sex adjusted 0.96 (0.94-0.98) 
Multivariable* 1.00 (0.97-1.02) 
 
Each model includes a random intercept at the country-level. *The multivariable model adjusted for 
the following variables: age, sex, smoking status, atrial fibrillation/flutter, height, weight, Canadian 
Cardiovascular Society Class IV, New York Heart Association class, coronary artery disease, 
pulmonary hypertension, aortic valve area, left ventricular ejection fraction, non-elective procedure 
indication, non-transfemoral access route. CI: confidence interval, OR: odds ratio, HR: hazard ratio. 
VARC: Valve Academic Research Consortium. 
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Table 3: Hazard Ratios for Long-term Survival and Length of Stay, and Odds Ratios for 
the VARC-2 Composite Early Safety Across Strata of Charlson Comorbidity Index (CCI) 
 
Long-term survival 
HR of CCI=1 vs 
CCI=0 (95% CI) 
HR of CCI=2 vs 
CCI=0 (95% CI) 
HR of CCI≥3 vs 
CCI=0 (95% CI) 
Univariable 1.19 (0.68-2.10) 1.80 (1.06-3.05) 2.30 (1.41-3.76) 
Age and Sex adjusted 1.21 (0.69-2.13) 1.86 (1.10-3.16) 2.36 (1.44-3.86) 
Multivariable* 1.17 (0.66-2.06) 1.73 (1.01-2.94) 2.18 (1.32-3.61) 
    
Length of stay 
HR of CCI=1 vs 
CCI=0 (95% CI) 
HR of CCI=2 vs 
CCI=0 (95% CI) 
HR of CCI≥3 vs 
CCI=0 (95% CI) 
Univariable 1.13 (0.89-1.43) 1.17 (0.93-1.47) 0.96 (0.77-1.18) 
Age and Sex adjusted 1.12 (0.89-1.43) 1.17 (0.93-1.47) 0.95 (0.77-1.18) 
Multivariable* 1.31 (1.02-1.67) 1.41 (1.11-1.79) 1.27 (1.02-1.59) 
    
VARC-2 Early Safety 
OR of CCI=1 vs 
CCI=0 (95% CI) 
OR of CCI=2 vs 
CCI=0 (95% CI) 
OR of CCI≥3 vs 
CCI=0 (95% CI) 
Univariable 0.98 (0.48-1.98) 0.63 (0.30-1.32) 1.14 (0.60-2.15) 
Age and Sex adjusted 0.99 (0.49-2.00) 0.64 (0.31-1.34) 1.16 (0.61-2.20) 
Multivariable* 0.94 (0.45-1.94) 0.57 (0.27-1.21) 0.94 (0.48-1.85) 
 
Patients with CCI=0 were used as the reference group. Each model includes a random intercept at the 
country-level. *The multivariable model adjusted for the following variables: age, sex, smoking status, 
atrial fibrillation/flutter,  height, weight, Canadian Cardiovascular Society Class IV, New York Heart 
Association Class, coronary artery disease, pulmonary hypertension, aortic valve area, left ventricular 
ejection fraction, non-elective procedure indication, non-transfemoral access route. CI: confidence 
interval, OR: odds ratio, HR: hazard ratio, VARC: Valve Academic Research Consortium. 
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Figures legends 
Figure 1: Distribution of total Charlson Comorbidity Index (CCI) as a Whole Cohort 
and by Country. UK: United Kingdom.  
 
Figure 2: Proportion of Patients Within Each Charlson Comorbidity Index (CCI) 
Strata Across Quantile of Predicted Risk Models. LES: logistic EuroSCORE, ESII: 
EuroSCORE-II, STS: Society of Thoracic Surgeons. 
 
Figure 3: Kaplan-Meier for Long-term Survival by Charlson Comorbidity Index (CCI) 
strata. TAVI: transcatheter aortic valve implantation. 
 
Figure 4: Forest Plot of (multivariable adjusted) Hazard Ratios for Long-term Survival 
(top panel) and Length of Stay (bottom panel). Data from a two-stage individual 
participant data random-effect meta-analysis. UK: United Kingdom. CCI: Charlson 
Comorbidity Index. 
 
Figure 5. Multivariable adjusted hazard ratio for shorter length of stay as a smooth 
function of total Charlson Comorbidity Index (CCI). 
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SUPPLEMENTARY MATERIAL 
 
Supplementary Figure 1: Proportion of Patients Within Each Charlson Comorbidity Index 
(CCI) Strata Across Country. 
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Supplementary Figure 2: Prevalence of each Charlson Comorbidity Index (CCI) component. 
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Supplementary Figure 3: Forest plot of odds ratios for 30-day mortality from a two-stage 
individual participant data meta-analysis; estimates adjusted for the following variables: age, sex, 
smoking status, atrial fibrillation/flutter, height, weight, Canadian Cardiovascular Society Class 
IV, New York Heart Association, coronary artery disease, and aortic valve area. Charlson 
Comorbidity Index (CCI). UK: United Kingdom. 
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Supplementary Figure 4: Forest plot of (multivariable adjusted) hazard ratios (HRs) for length 
of stay from a two-stage individual participant data random-effect meta-analysis across strata of 
total Charleston Comorbidity Index (CCI). UK: United Kingdom. 
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Supplementary Table 1: Baseline patient characteristics across each country of data origin. 
Variable UK (n=791) Canada (n=308) Italy (n=181) Spain (n=375) Switzerland (n=232) P-value 
Age, mean (min-
max) 
80.9 (23-94) 81.0 (50-96) 81.0 (40-94) 83.0 (61-95) 82.5 (44-95) <0.001 
Male, n (%) 
[missing] 
455 (57.5) 160 (51.9) 88 (48.6) 144 (38.4) 123 (53.0) <0.001 
Diabetic, n (%) 
[missing] 
221 (27.9) 112 (36.4) 56 (30.9) 127 (33.9) [2] 48 (20.7) <0.001 
Current or Ex-
Smoker, n (%) 
[missing] 
498 (63.0) [1] 124 (40.3) [5] 39 (21.5) 89 (23.7) [1] N/A [232] <0.001 
Creatinine, mean 
(min-max) 
[missing] 
114.1 (38-638) 103.3 (36-427) 120.4 (6.2-557) [3] 100.7 (44-408) 101.1 (0.0-579) <0.001 
Dialysis, n (%) 
[missing] 
10 (1.26) 5 (1.62) N/A [181] 3 (0.80) N/A [232] 0.614 
Previous MI, n (%) 210 (26.5) 74 (24.0) 40 (22.1) 73 (19.5) 32 (13.8) 0.001 
Pulmonary Disease, 
n (%) [missing] 
222 (28.1) [1] 86 (27.9) [4] 43 (23.8) 79 (21.1) 39 (16.8) 0.002 
Neurological 
Disease, n (%) 
[missing] 
174 (22.0) 55 (17.9) [1] 21 (11.6) 42 (11.2%) [1] 28 (12.1) <0.001 
Extracardiac 
Arteriopathy, n (%) 
[missing] 
243 (30.7) 53 (17.2) [1] 26 (14.4) 28 (7.47) [1] 51 (22.0) <0.001 
Atrial 
Fibrillation/Flutter, 
216 (27.3) [6] 77 (25.0) [1] 86 (47.5) 107 (28.5) 63 (27.2) [3] <0.001 
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n (%) [missing] 
Previous Cardiac 
Surgery, n (%) 
[missing] 
216 (27.3) 146 (47.4) 55 (30.4) 43 (11.5) 19 (8.19) <0.001 
Previous BAV, n 
(%) [missing] 
55 (6.95) [89] N/A [308] N/A [181] 196 (52.3) 71 (30.6) <0.001 
Previous PCI, n (%) 
[missing] 
191 (24.1) [1] N/A [308] 43 (23.8) [4] 83 (22.1) 50 (21.6) 0.797 
Height, mean (min-
max) [missing] 
1.66 (1.32-1.90) 
[6] 
1.66 (1.41-1.90) 
[8] 
N/A [181] 1.59 (1.33-1.85) 1.65 (1.40-1.87) [18] <0.001 
Weight, mean 
(min-max) 
[missing] 
74.8 (40.0-132.0) 
[7] 
76.0 (41-136) [6] N/A [181] 70.5 (42-120) 72.4 (41-124) [18] <0.001 
CCS IV, n (%) 
[missing] 
13 (1.64) 7 (2.27) [229] N/A [181] N/A [375] N/A [232] 0.653 
NYHA III/IV, n 
(%) [missing] 
750 (94.8) 283 (91.9) [1] 93 (51.4) 276 (73.6) [11] 144 (62.1) <0.001 
Coronary Artery 
Disease, n (%) 
[missing] 
362 (45.8) [4] 209 (67.9) 94 (51.9) 178 (47.5) 117 (50.4) <0.001 
Pulmonary 
Hypertension, n 
(%) [missing] 
47 (5.94) [227] N/A [308] 33 (18.2) [18] 164 (43.7) [11] 21 (9.05) [81] <0.001 
Aortic Valve area, 
mean (min-max) 
[missing] 
0.69 (0.20-3.0) 
[27] 
N/A [308] 
0.70 (0.30-3.71) 
[10] 
0.61 (0.20-4.0) 
[62] 
0.73 (0.40-2.8) [22] <0.001 
LVEF<50%, n (%) 
[missing] 
424 (53.6) [1] 74 (24.0) [8] 44 (24.3) [2] 84 (22.4) [0] 65 (28.0) [16] <0.001 
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Non-elective 
procedure, n (%) 
[missing] 
176 (22.3) [1] 37 (12.0) 4 (2.21) N/A [375] N/A [232] <0.001 
Non-TF Access, n 
(%) [missing] 
111 (14.0) 129 (41.9) 54 (29.8) 0 (0) 35 (15.1) <0.001 
Logistic 
EuroSCORE, mean 
% (min-max)* 
27.4 (2.2-98) 26.6 (2.8-87.4) 22.9 (2.01-79.5) 22.3 (1.72-83.4) 19.3 (3.25-69.5) <0.001 
STS-Score, mean 
% (min-max)* 
5.80 (0.59-48.6) 5.02 (0.98-22.0) 5.25 (0.79-32.0) 4.41 (0.76-20.5) 5.67 (0.89-22) <0.001 
EuroSCORE II, 
mean % (min-
max)* 
10.1 (0.78-66.0) 9.12 (1.21-49.3) 7.21 (0.91-41.3) 5.69 (0.96-38.9) 5.59 (1.02-29.5) <0.001 
FRANCE-2, mean 
% (min-max)* 
9.29 (3.49-40.6) 10.0 (3.49-32.8) 9.83 (4.16-33.7) 7.19 (3.49-28.9) 10.9 (3.49-34.1) <0.001 
Outcomes       
30-day mortality, n 
(%) 
20/567 (3.53) 15/308 (4.87) 5/162 (3.09) 25/375 (6.67) 3/232 (1.29) 0.016 
1-Year survival, % 86.3 94.8 75.1 82.0 95.7 <0.001 
Length of Stay, 
median (days) 
7 6 13 7 7 <0.001 
VARC-2 Early 
safety, n (%) 
134/661 (20.3) 32/300 (10.7) 46/181 (25.4) N/A N/A <0.001 
 
Cells denoted with “N/A” indicate 100% missing data for that particular country/variable combination. *The Logistic EuroSCORE, STS-Score and 
EuroSCORE II each aim to predict short-term mortality following cardiac surgery; the FRANCE-2 model is a TAVI specific model to estimate 30-day 
mortality risk. All risk models were calculated here using the multiple imputed data. UK: United Kingdom. MI: myocardial infarction. BAV: balloon-aortic 
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valvuloplasty. PCI: percutaneous coronary intervention. CCS: Canadian Cardiovascular Society. NYHA: New York Heart Association. LVEF: left ventricular 
ejection fraction. TF: transfemoral. VARC: Valve Academic Research Consortium.  
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 1
STROBE Statement - Checklist of items that should be included in reports of observational studies 
 
 Item 
No 
Checklist of item Reported on page # 
Title and abstract 1 
(a) Indicate the study’s design with a commonly used term in the title or the abstract 1 and 2 
(b) Provide in the abstract an informative and balanced summary of what was done and what was found 1 and 2 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 5 
Objectives 3 State specific objectives, including any pre-specified hypotheses 5 
Methods  
Study design 4 Present key elements of study design early in the paper 5 and 6 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection 5 and 5 
Participants 6 
(a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of 
follow-up 
Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. 
Give the rationale for the choice of cases and controls 
Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants 
5 and 6 
Variables 7 
Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if 
applicable 
7 
Data sources/ 
measurement 
8* 
For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe 
comparability of assessment methods if there is more than one group 
7 and 8 
Bias 9 Describe any efforts to address potential sources of bias 8 
Study size 10 Explain how the study size was arrived at 5 and 6 
Quantitative variables 11 
Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and 
why 
6 to 8 
Statistical methods 12 
(a) Describe all statistical methods, including those used to control for confounding 6 to 8 
(b) Describe any methods used to examine subgroups and interactions 6 to 8 
(c) Explain how missing data were addressed 6 to 8 
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 2
Results  
Participants 13* 
(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, 
included in the study, completing follow-up, and analysed 
9 
(b) Give reasons for non-participation at each stage Not Applicable 
(c) Consider use of a flow diagram Not Applicable 
Descriptive 
data 
14* 
(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential 
confounders 
9 
(b) Indicate number of participants with missing data for each variable of interest 
Table 1 and 
Supplementary Table 1 
(c) Cohort study—Summarise follow-up time (eg, average and total amount) 10 
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 9 to 12 
Main results 16 
(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). 
Make clear which confounders were adjusted for and why they were included 
10 and 11 
(b) Report category boundaries when continuous variables were categorized 9 to 11 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period As Hazzard Ratio 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Not Applicable 
Discussion  
Key results 18 Summarise key results with reference to study objectives 12 
Limitations 19 
Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of 
any potential bias 
14 
Interpretation 20 
Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar 
studies, and other relevant evidence 
15 
Generalisability 21 Discuss the generalisability (external validity) of the study results 13 and 14 
Other information  
Funding 22 
Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the 
present article is based 
1 
 
*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies. 
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE 
checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org. 
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